AI Summary & Key Takeaways
AI InsightFurther experimental and clinical studies should focus on the pathobiology and proper clinical management of the myeloproliferative neo-plasm patients with hemostatic complications.
📌 3 Key Takeaways
Özet
Objective: Thrombohemorrhagic events developing in the Philadelphia neg-ative myeloproliferative neoplasms may worsen the clinical course of the dis-ease and increase the morbidity and mortality. The aim of this study is to as-sess critical risk factors of the hemostatic complications in myeloprolifera-tive neoplasms.Materials and Methods: The patients who were diagnosed as myeloprolif-erative neoplasm based on world health organization 2016 criteria are in-cluded into the study. The categorical and continuous data were compared with Chi-square and independent sample t-test. The statistical significance threshold was considered as p <0.05.Results: 181 patients were evaluated in this study. The number of the pa-tients with polycythemia vera, essential thrombocytosis and primary myelo-fibrosis were 89, 50 and 42 respectively. At the time of diagnosis, the median age was 54 years. There were 50 patients who had thrombosis at the time of diagnosis, and 22 patients have developed thrombosis during the follow-up. Venous thrombosis is more frequent than arterial thrombosis. The smoking habit was statistically higher in the patient with myeloproliferative neoplasm who developed thrombosis (p=0.006). The most frequent hemorrhagic com-plication was gastrointestinal bleeding. Platelet levels of patients with com-plications during the course of myeloproliferative neoplasm were found to be lower than those without complications (p <0.001).Conclusion: The hemostatic complication rates due to myeloproliferative neoplasm were 39% thrombosis and 13% bleeding. While the cigarette us-age was significantly higher in the thrombosis group, advanced age, male sex, types of myeloproliferative neoplasm, JAK-2 positivity were similar between the groups. Further experimental and clinical studies should focus on the pathobiology and proper clinical management of the myeloproliferative neo-plasm patients with hemostatic complications.